Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Oncology Today with Dr Neil Love
00:00
Retreatment After TDXD-Related ILD
Hope summarizes pooled analyses and recommends against re-challenge after symptomatic (grade ≥2) ILD.
Play episode from 30:47
Transcript
